PE20160012A1 - Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral - Google Patents

Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral

Info

Publication number
PE20160012A1
PE20160012A1 PE2015002367A PE2015002367A PE20160012A1 PE 20160012 A1 PE20160012 A1 PE 20160012A1 PE 2015002367 A PE2015002367 A PE 2015002367A PE 2015002367 A PE2015002367 A PE 2015002367A PE 20160012 A1 PE20160012 A1 PE 20160012A1
Authority
PE
Peru
Prior art keywords
administration
myopathic
treatment
protein
neurogenerative diseases
Prior art date
Application number
PE2015002367A
Other languages
English (en)
Inventor
Dalia Megiddo
Original Assignee
Bio Blast Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Blast Pharma Ltd filed Critical Bio Blast Pharma Ltd
Publication of PE20160012A1 publication Critical patent/PE20160012A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Abstract

Se divulga una formulacion farmaceutica acuosa inyectable que comprende una cantidad terapeuticamente efectiva de trehalosa, donde la concentracion de trehalosa es entre 0.1% (p/v) a 50 % (p/v)
PE2015002367A 2013-05-07 2014-05-07 Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral PE20160012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07

Publications (1)

Publication Number Publication Date
PE20160012A1 true PE20160012A1 (es) 2016-02-14

Family

ID=51022384

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002367A PE20160012A1 (es) 2013-05-07 2014-05-07 Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral

Country Status (15)

Country Link
US (4) US10493023B2 (es)
EP (2) EP2994145B1 (es)
JP (4) JP6837835B2 (es)
KR (1) KR20160009617A (es)
AU (4) AU2014264228A1 (es)
CA (1) CA2911399A1 (es)
CR (1) CR20150637A (es)
EA (1) EA201501054A1 (es)
HK (1) HK1217300A1 (es)
IL (1) IL241757B (es)
MD (1) MD20150120A2 (es)
MX (1) MX2015015355A (es)
PE (1) PE20160012A1 (es)
SG (1) SG11201509030TA (es)
WO (1) WO2014181333A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
JP6837835B2 (ja) 2013-05-07 2021-03-03 バイオ・ブラスト・ファーマ・リミテッドＢｉｏ Ｂｌａｓｔ Ｐｈａｒｍａ Ｌｔｄ． トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
US10736909B2 (en) 2016-02-08 2020-08-11 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
MX2018012902A (es) 2016-04-21 2019-06-06 Baylor College Medicine Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EP3668509B1 (en) 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
IL295562A (en) * 2020-02-13 2022-10-01 Prilenia Neurotherapeutics Ltd Treatment of muscular dystrophy (ALS) by combining pridopidine and another active substance
WO2022013940A1 (ja) * 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS516109B2 (es) 1972-12-28 1976-02-25
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
AU1172097A (en) 1995-12-27 1997-07-28 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
EP1600143B1 (en) 2003-02-13 2019-07-10 Hayashibara Co., Ltd. SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
EP1888095A4 (en) * 2005-05-13 2009-08-26 Whitehead Biomedical Inst MODULATORS OF ALPHA SYNUCLEINE TOXICITY
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
US20090110671A1 (en) 2005-08-11 2009-04-30 Satomi Miyata Agent for enhanching the production of collagen and it's use
WO2007063902A1 (ja) 2005-11-30 2007-06-07 The Nisshin Oillio Group, Ltd. トレハロース脂肪酸エステル組成物
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
JP5114627B2 (ja) 2006-03-27 2013-01-09 株式会社糖鎖工学研究所 トレハロース化合物および該化合物を含有する医薬
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
EP2123662B1 (en) 2007-01-31 2013-12-04 Glytech, Inc. Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound
CN101646442B (zh) 2007-02-23 2013-09-04 21世纪国际新技术株式会社 血管痉挛的治疗剂或预防剂
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
JP2011502125A (ja) * 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 小分子拡散を促進する新しい種類の治療法
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
WO2010008860A1 (en) 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
WO2010050178A1 (ja) 2008-10-31 2010-05-06 大塚化学株式会社 トレハロース化合物、その製造方法、及び該化合物を含有する医薬
US20110293605A1 (en) * 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
WO2011108762A1 (ja) * 2010-03-05 2011-09-09 株式会社林原生物化学研究所 インスリン抵抗性の予防及び／又は改善剤
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
US20140066439A1 (en) * 2010-11-10 2014-03-06 Katholieke Universiteit Leuen, K.U.Leuven R&D Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6837835B2 (ja) 2013-05-07 2021-03-03 バイオ・ブラスト・ファーマ・リミテッドＢｉｏ Ｂｌａｓｔ Ｐｈａｒｍａ Ｌｔｄ． トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof

Also Published As

Publication number Publication date
AU2019204513A1 (en) 2019-07-18
MD20150120A2 (ro) 2016-03-31
US20190374463A1 (en) 2019-12-12
EP2994145B1 (en) 2023-01-04
US10869831B2 (en) 2020-12-22
CR20150637A (es) 2016-04-05
EP4218769A3 (en) 2023-10-18
IL241757B (en) 2020-05-31
US20240009113A1 (en) 2024-01-11
AU2020277197A1 (en) 2020-12-24
WO2014181333A2 (en) 2014-11-13
WO2014181333A3 (en) 2015-01-08
AU2023200303A1 (en) 2023-02-23
US20220117883A1 (en) 2022-04-21
JP6837835B2 (ja) 2021-03-03
JP2016518403A (ja) 2016-06-23
AU2019204513B2 (en) 2020-09-10
KR20160009617A (ko) 2016-01-26
US10493023B2 (en) 2019-12-03
SG11201509030TA (en) 2015-11-27
JP2023040211A (ja) 2023-03-22
JP2019142907A (ja) 2019-08-29
US20160120798A1 (en) 2016-05-05
EA201501054A1 (ru) 2016-04-29
HK1217300A1 (zh) 2017-01-06
AU2014264228A1 (en) 2015-11-12
EP4218769A2 (en) 2023-08-02
MX2015015355A (es) 2016-07-18
CA2911399A1 (en) 2014-11-13
EP2994145A2 (en) 2016-03-16
JP2021152032A (ja) 2021-09-30

Similar Documents

Publication Publication Date Title
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
AR107014A1 (es) Formulación farmacéutica acuosa
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
AR098168A1 (es) Formulación estable de insulina glulisina
CL2015002456A1 (es) Tratamiento de la deficiencia de la hormona del crecimiento pediátrica con análogos de la hormona del crecimiento humano
EA202090683A3 (ru) Способы и композиции для лечения рака
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2015002835A1 (es) Nuevos derivados de piridina
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal